Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reltecimod versus placebo for sepsis-associated acute kidney injury
NL-OMON48294Phase 2Not yet recruiting
- Sponsor
- Atox Bio
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis-associated acute kidney injury (S-AKI) comparing Reltecimod + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Complete recovery at Day 14 and Safety and tolerability. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
reltecimod
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on NL-OMON48294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48294.